AVBP ArriVent BioPharma, Inc.
Nasdaq · SEC CIK 1868279 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $12.98M 1 sales by 1 insiders
- Filings on record
- 30 since 2024-01-29, latest 2026-06-22 21:51
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| HHLR ADVISORS, LTD. | 10% | — | $12.98M |
Transactions 11
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-02-03 | 2025-12-10 | AVBP | HHLR ADVISORS, LTD. | 10% | S - Sale | $23.37 | -555.6K | 3.93M | -12% | -$12.98M |
| DM | 2025-07-15 | 2025-07-11 | AVBP | LaChapelle Robin | COO | M - OptEx | $2.28 | +11.2K | 129.2K | +9% | +$25.4K |
| DM | 2024-09-23 | 2024-09-19 | AVBP | LaChapelle Robin | COO | M - OptEx | $3.28 | +27.6K | 102.6K | +37% | +$90.5K |
| DMI | 2024-02-01 | 2024-01-30 | AVBP | HHLR ADVISORS, LTD. | 10% | C - Cnv Deriv | — | +3.93M | 3.62M | New | — |
| DI | 2024-02-01 | 2024-01-30 | AVBP | HHLR ADVISORS, LTD. | 10% | P - Purchase | $18.00 | +555.6K | 4.48M | +14% | +$10.00M |
| DI | 2024-01-31 | 2024-01-30 | AVBP | HEALY JAMES | Dir | C - Cnv Deriv | — | +1.25M | 1.25M | New | — |
| DI | 2024-01-31 | 2024-01-30 | AVBP | HEALY JAMES | Dir | P - Purchase | $18.00 | +444.4K | 1.70M | +35% | +$8.00M |
| DMI | 2024-01-31 | 2024-01-30 | AVBP | OrbiMed Asia GP IV, L.P. | Dir, 10% | P - Purchase | $18.00 | +444.4K | 1.51M | +42% | +$8.00M |
| DMI | 2024-01-31 | 2024-01-30 | AVBP | OrbiMed Asia GP IV, L.P. | Dir, 10% | C - Cnv Deriv | — | +2.58M | 821.8K | New | — |
| DMI | 2024-01-31 | 2024-01-30 | AVBP | GORDON CARL L | Dir, 10% | C - Cnv Deriv | — | +2.58M | 821.8K | New | — |
| DMI | 2024-01-31 | 2024-01-30 | AVBP | GORDON CARL L | Dir, 10% | P - Purchase | $18.00 | +444.4K | 1.51M | +42% | +$8.00M |